Estela Cristina Prieto Maillo*, Ana Gabriela Salazar Palacios, Ana Maria Martin Varillas, Jose Luis Fernandez Sanchez, Sergio Cadenas Menendez and Amparo Rosa Sanchez Serrano
Volume6-Issue1
Dates: Received: 2024-12-15 | Accepted: 2025-01-31 | Published: 2025-01-31
Pages: 117-119
Abstract
Denosumab is an antiresorptive monoclonal antibody widely used in the treatment of osteoporosis.
A rare and potentially life-threatening adverse reaction likely associated with denosumab treatment is described, presenting as the first case report in the English literature of non-specific interstitial pneumonia (NSIP), to the best of our knowledge. The importance of clinically recognising drug-induced manifestations is evidenced in this case, where early withdrawal of the drug is usually associated with a clinical-prognostic improvement.
FullText HTML
FullText PDF
DOI: 10.37871/jbres2062
Certificate of Publication
Copyright
© 2025 Prieto Maillo EC, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Prieto Maillo EC, Salazar Palacios AG, Martin Varillas AM, Fernandez Sanchez JL, Menendez SC, Sanchez Serrano AR. Non-Specifi c Interstitial Pneumonia in a Woman with Osteoporosis Treated with Denosumab. J Biomed Res Environ Sci. 2025 Jan 31; 6(1): 117-119. doi: 10.37871/jbres2062, Article ID: JBRES2062, Available at: https://www.jelsciences.com/articles/jbres2062.pdf
Subject area(s)
References
- Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2018 Oct 22;10(11):209-223. doi: 10.1177/1759720X18805759. PMID: 30386439; PMCID: PMC6204627.
- Liu W, Zhang X. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review). Mol Med Rep. 2015 May;11(5):3212-8. doi: 10.3892/mmr.2015.3152. Epub 2015 Jan 7. PMID: 25572286.
- Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, Giollo A, Wild JM, Waterton JC, Buch M, Linton K, Bruce IN, Leonard C, Bianchi S, Chaudhuri N. Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018 Oct 15;7(10):356. doi: 10.3390/jcm7100356. PMID: 30326612; PMCID: PMC6209877.
- Ruiz AC, Carrascosa MF, Concha ST, Gil AH, Rivero JG. Interstitial Lung Disease in a Patient Treated with Denosumab. Eur J Case Rep Intern Med. 2019 Jul 3;6(7):001131. doi: 10.12890/2019_001131. PMID: 31410352; PMCID: PMC6663050.
- Mori Y, Izumiyama T, Mori N, Aizawa T. Interstitial lung disease in a woman with rheumatoid arthritis treated with denosumab: A case report. Mod Rheumatol Case Rep. 2022 Jun 24;6(2):155-159. doi: 10.1093/mrcr/rxab046. PMID: 34791403.
- Komada F, Nakayama Y, Takara K. [Analysis of Time-to-onset and Onset-pattern of Interstitial Lung Disease after the Administration of Monoclonal Antibody Agents]. Yakugaku Zasshi. 2018;138(12):1587-1594. Japanese. doi: 10.1248/yakushi.18-00094. PMID: 30504674.